$204 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 4 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARCELLX INC. | $99,440,000 | +29.0% | 5,500,007 | 0.0% | 48.67% | +23.3% | ||
| DSGN | DESIGN THERAPEUTICS INC | $78,771,000 | -13.3% | 5,626,476 | 0.0% | 38.55% | -17.1% | |
| EFFECTOR THERAPEUTICS INC | $9,687,000 | -64.6% | 6,822,114 | 0.0% | 4.74% | -66.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
| EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
| ARCELLX INC. | 7 | Q3 2023 | 72.6% |
| NKARTA INC. | 6 | Q3 2023 | 8.0% |
| ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
| MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR/A | 2023-05-19 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.